RecruitingNot ApplicableNCT06162403

Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study

Sponsor

M.D. Anderson Cancer Center

Enrollment

10 participants

Start Date

Feb 22, 2024

Study Type

INTERVENTIONAL

Conditions

Chemotherapy Induced Peripheral Neuropathy Peripheral Nerve Stimulation

Summary

To learn if peripheral nerve stimulation (PNS) can help to improve pain in participants with CIPN.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria4

Participants diagnosed with chronic (≥90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds or ionizing irradiation) of the lower extremity, seen at Pain Management Center at MD Anderson Cancer Center
Participants reports baseline pain ≥ 4 (0-10 scale, NRS)
Participants between ages 18-85 years old
Participants who have completed chemotherapy within the previous year at the time of enrollment

Exclusion Criteria5

Participants with cognitive dysfunction
Participants with recent history (<6 months) of drug or alcohol abuse
Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection
Participants with allergies to local anesthesia, steroids, or adhesives
Participants with conditions that conflict with the SPRINT PNS System Indications for Use, including Contraindications and Warnings.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPeripheral Nerve Stimulation

The leads are inserted through a needle. If needed, the study team may give participants anesthetic (for example, as a cream/gel on your skin and/or as an injection) to numb the area where the leads will be injected.